Compare DKL & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKL | DYN |
|---|---|---|
| Founded | 2012 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2012 | 2020 |
| Metric | DKL | DYN |
|---|---|---|
| Price | $50.58 | $20.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $51.33 | $37.00 |
| AVG Volume (30 Days) | 45.4K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.73 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.18 | $8.25 |
| 52 Week High | $55.89 | $25.00 |
| Indicator | DKL | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 60.89 |
| Support Level | $50.17 | $18.32 |
| Resistance Level | $55.20 | $21.00 |
| Average True Range (ATR) | 1.63 | 1.08 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 66.23 | 66.31 |
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.